Table 6.
Variable | Visit | Group | n | CST I n (%) |
CST III n (%) |
CST IV n (%) |
P valuea |
---|---|---|---|---|---|---|---|
Trial arm | ANC1 | Iron | 144 | 70 (48.6) | 39 (27.1) | 35 (24.3) | 0.518 |
Control | 136 | 61 (44.9) | 45 (33.1) | 30 (22.1) | |||
FINb | Iron | 349 | 121 (34.7) | 88 (25.2) | 140 (40.1) | 0.113 | |
Control | 341 | 140 (1.1) | 66 (19.4) | 135 (9.6) | |||
Iron deficiency, Adjusted ferritin | ANC1 | No | 249 | 118 (47.4) | 75 (30.1) | 56 (22.5) | 0.57 |
Yes | 27 | 10 (37.0) | 9 (33.3) | 8 (29.6) | |||
FINb | No | 620 | 237 (38.2) | 140 (22.6) | 243 (39.2) | 0.281 | |
Yes | 65 | 20 (30.8) | 13 (20.0) | 32 (49.2) | |||
Ratio sTfR/log ferritin | ANC1 | No | 247 | 120 (48.6) | 74 (30.0) | 53 (21.5) | 0.216 |
Yes | 32 | 11 (34.4) | 10 (31.2) | 11 (34.4) | |||
FINb | No | 544 | 205 (37.7) | 124 (22.8) | 215 (39.5) | 0.81 | |
Yes | 140 | 52 (37.1) | 29 (20.7) | 59 (42.1) | |||
Nugent scorec | ANC1 | 7-10 | 15 | 0 (0) | 1 (6.7) | 14 (93.3) | <0.001 |
4-6 | 31 | 7 (22.6) | 6 (19.4) | 18 (58.1) | <0.001 | ||
0-3 | 221 | 116 (52.5) | 74 (33.5) | 31 (14.0) | <0.001 | ||
FINb | 7-10 | 80 | 2 (2.5) | 6 (7.5) | 72 (90.0) | <0.001 | |
4-6 | 60 | 11 (18.3) | 6 (10.0) | 43 (71.7) | <0.001 | ||
0-3 | 501 | 232 (46.3) | 132 (26.3) | 137 (27.3) | <0.001 | ||
T. vaginalis | ANC1 | No | 243 | 121 (49.8) | 73 (30.0) | 49 (20.2) | 0.006 |
Yes | 37 | 10 (27.0) | 11 (29.7) | 16 (43.2) | |||
FINb | No | 655 | 260 (39.7) | 149 (22.7) | 246 (37.6) | <0.001 | |
Yes | 35 | 1 (2.9) | 5 (14.3) | 29 (82.9) | |||
High pH ≥ 4.5 | ANC1 | No | 123 | 73 (59.3) | 37 (30.1) | 13 (10.6) | <0.001 |
Yes | 153 | 58 (37.9) | 45 (29.4) | 50 (32.7) | |||
Vaginal discharge | ANC1 | No | 260 | 122 (46.9) | 80 (30.8) | 58 (22.3) | 0.268 |
Yes | 20 | 9 (4.5) | 4 (20.0) | 7 (35.0) | |||
FINb | No | 618 | 232 (37.5) | 144 (23.3) | 242 (39.2) | 0.205 | |
Yes | 69 | 28 (40.6) | 10 (14.5) | 31 (44.9) | |||
Antibiotics within previous three months | ANC1 | No | 252 | 118 (46.8) | 73 (29.0) | 61 (24.2) | NA |
Yes | 28 | 13 (46.4) | 11 (39.3) | 4 (14.3) | |||
FINb | No | 616 | 236 (38.3) | 136 (22.1) | 244 (39.6) | NA | |
Yes | 74 | 25 (33.8) | 18 (24.3) | 31 (41.9) |
a P value for association between status and CST from a multinomial regression model adjusting for antibiotic use in the 3 months prior to assessment
bMenarcheal women only
cEach Nugent group compared to the other two. BV corresponds to Nugent score 7–10
ANC1 first antenatal visit, CST community state type, FIN end assessment, sTfR serum transferrin receptor